Intersect ENT (XENT) Reports In-Line Q4 EPS, Slight Beat on Revenues; Offers Q1 & FY19 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Intersect ENT (XENT) Reports In-Line Q4 EPS, Slight Beat on Revenues; Offers Q1 & FY19 Revenue Guidance Below Consensus

Intersect ENT Reports Fourth Quarter and Full Year 2018 Results

February 25, 2019 4:05 PM EST

ENCORE Clinical Study Completed, Primary Endpoints Met

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and full year ended December 31, 2018.

Recent Business Highlights

In December 2018, the company commenced enrollment in the study of its newest platform product, the ASCEND investigational drug-coated sinus balloon. This novel device is designed to deliver a corticosteroid (mometasone furoate)... More